# Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in China

> **NCT03410706** · — · COMPLETED · sponsor: **Bayer** · enrollment: 288 (actual)

## Conditions studied

- Pulmonary Embolism

## Interventions

- **DRUG:** Rivaroxaban(Xarelto, BAY 59-7939)

## Key facts

- **NCT ID:** NCT03410706
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-01
- **Primary completion:** 2021-07-29
- **Final completion:** 2021-12-24
- **Target enrollment:** 288 (ACTUAL)
- **Last updated:** 2022-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03410706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03410706, "Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in China". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03410706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*